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Abbreviations 
 
25OHD  25-hydroxyvitamin D 
1,25(OH)2D  1,25-dihydroxyvitamin D  
BMD   Bone mineral density 
Bone ALP  Bone alkaline phosphatase 
CTX    C-terminal telopeptide of type I collagen 
DBP   Vitamin D binding protein 
DXA   Dual-energy X-ray absorptiometry 
HR-pQCT  High resolution peripheral quantitative tomography 
LC-MS/MS   Liquid chromatography tandem mass spectrometry  
PINP   procollagen type I N propeptide 
PTH   Parathyroid hormone 
SPPB   Short physical performance battery 
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Abstract 1 
Background: The mechanism and clinical significance of low circulating 25-hydroxyvitamin 2 
D (25OHD) in obese people are unknown. Low total 25OHD may be due to low vitamin D 3 
binding proteins (DBP) or faster metabolic clearance. Obese people have higher bone mineral 4 
density (BMD), suggesting that the low total 25OHD may not have the expected adverse 5 
consequences for bone. 6 
Objective: The aims of this study were to determine whether 1) vitamin D metabolism and 2) 7 
its association with bone health differ by body weight. 8 
Design: We conducted a cross-sectional observational study of 223 normal weight, 9 
overweight and obese men and women ages 25 to 75 in South Yorkshire, UK in fall/spring. A 10 
subgroup of 106 were also assessed in winter. We used novel techniques including an 11 
immunoassay for free 25OHD, stable isotope for 25OHD3 half-life, and high resolution 12 
quantitative tomography (HR-pQCT) to make a detailed assessment of vitamin D physiology 13 
and bone health. 14 
Results: Total serum 25OHD was lower in obese and overweight than normal weight people 15 
in fall/spring (geometric means 45.0 and 40.8 vs 58.6 nmol/l, p<0.001), but not in winter. 16 
Serum 25OHD was inversely correlated with BMI in fall/spring and winter. 17 
Free 25OHD measured by immunoassay or calculated from DBP and albumin was lower in 18 
obesity. DBP, DBP genotype, and 25OHD3 half-life did not differ between BMI groups. 19 
Bone turnover was lower and bone density was higher in obese people. 20 
Conclusions: Total and free 25OHD and 1,25(OH)2D are lower at higher body weight, and 21 
this can’t be explained by lower DBP or shorter half-life of 25OHD3. However, obese people 22 
had lower bone turnover and higher bone density than normal weight. 23 
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We speculate that low 25OHD in obesity is due to greater pool of distribution.  Lower 24 
25OHD in obesity may not reflect at-risk skeletal health. 25 
 26 
Keywords: vitamin D, obesity, vitamin D binding protein, half-life, bone density, bone 27 
turnover  28 
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Introduction 29 
Vitamin D is essential for intestinal absorption of dietary calcium and skeletal mineralisation. 30 
Vitamin D deficiency causes undermineralisation, increased bone resorption, osteomalacia 31 
and rickets. Vitamin D insufficiency is associated with increased risk of osteoporosis (1) and 32 
possibly poorer muscle function and other adverse health outcomes (2).  33 
Serum total 25-hydroxyvitamin D (25OHD) is the most commonly used biomarker for 34 
vitamin D status; it has a long plasma half-life and reflects both skin synthesis and oral 35 
intake. Recommended sufficiency levels are 50 to 75 nmol/l  (20 to 30 ng/ml) (3), (4).  36 
Serum total 25OHD is lower in obese people, and inversely correlated with BMI. This has 37 
been reported in adults and children of different ethnic groups all over the world. (5-13). 38 
However, the causes and clinical significance of the low 25OHD, and hence the value of total 39 
25OHD as a biomarker of vitamin D status in different body weights is not clear. 40 
Possible causes of low serum 25OHD in obesity are lower vitamin D supply (less sunlight 41 
exposure (14) or lower dietary intake (15)), greater volume of distribution, reduced biological 42 
availability or more rapid clearance.  43 
More than 99% of circulating 25OHD and 1,25(OH)2D are bound to vitamin D binding 44 
protein (DBP) and albumin, and the remaining free fraction is the most biologically available. 45 
Also, genetic polymorphism results in three DBP phenotypes, with differing circulating DBP 46 
levels and affinity for 25OHD (16, 17).  Lower concentrations of binding proteins would 47 
reduce total 25OHD measurements, but free 25OHD might be unchanged. It is not clear 48 
whether DBP levels differ by body weight (18, 19). 49 
Parathyroid hormone (PTH) may be increased in obesity (15, 20), and higher PTH could 50 
increase the metabolic clearance rate of 25OHD. 51 
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There is a paradox in body weight, vitamin D and bone; low 25OHD would be expected to be 52 
associated with higher bone and lower BMD, but BMI and fat mass are positively correlated 53 
with BMD (21), and higher body weight is generally protective against fracture (22). 54 
The aims of this study were to apply newly available techniques (including an immunoassay 55 
for free 25OHD and a stable isotope method for 25OHD3 half-life) to determine how vitamin 56 
D metabolism is affected by body weight, and a detailed assessment of bone (with multiple 57 
biochemical markers of bone turnover, dual energy X-ray absorptiometry (DXA) and high 58 
resolution peripheral quantitative CT (HR-pQCT)) to determine whether lower 25OHD 59 
affects bone health in obesity.  60 
 61 
Methods 62 
We conducted a cross-sectional study of healthy Caucasian men and women (ages 25 to 40 63 
and 55 to 75) from South Yorkshire, UK (latitude 53° N). 64 
Participants were approached through poster adverts, emails to hospital staff, mailing from 65 
general practice surgeries and a database of volunteers. Participants were recruited in three 66 
BMI categories: normal weight (BMI 18.5 to 24.9 kg/m
2
), overweight (BMI 25 to 29.9 67 
kg/m
2
), and obese (BMI >30 kg/m
2
). Exclusion criteria were: pregnancy or breast feeding 68 
within the last year, conditions (including diabetes) or medication (including hormonal 69 
contraception) known to affect vitamin D or bone metabolism, immobilisation, high alcohol 70 
intake, and competitive athletes. Older women were at least five years postmenopausal. There 71 
were no restrictions on supplement intake, and supplement use was included in the dietary 72 
calcium and vitamin D assessment. (For recruitment detail see Supplemental Table 1). 73 
The study was approved by South Yorkshire Research Ethics Committee, conducted 74 
according to the Declaration of Helsinki, and all subjects gave written informed consent.  75 
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All participants were assessed in fall or spring (19 September to 31 October 2012, and 2 76 
April to 16 May 2013) when UV-B is available. Fasting morning blood samples were taken 77 
for measurement of serum total and free 25OHD, 1,25(OH)2D, DBP, albumin, PTH, 78 
biochemical markers of bone turnover and DBP genotype. Statistical analyses were adjusted 79 
for date of visit. Sunlight exposure, dietary vitamin D intake and muscle function were also 80 
assessed. 81 
A subgroup of 106 participants were also assessed in winter (11 December 2012 to 1 April 82 
2013), to assess vitamin D status when there is negligible UV-B and avoid perturbation of the 83 
isotope tracer study by sunlight exposure. Fasting morning blood samples were taken for 84 
measurement of 25OHD, and 25OHD3 half-life was assessed with an isotope tracer. 85 
Measurements 86 
Short physical performance battery (SPPB) score (maximum score 12) was calculated from 87 
narrow walk and chair stand tests (23). Grip strength was measured using a digital 88 
dynamometer (Seahan Corp., Masan).  89 
The sunlight questionnaire was supplied by Prof Lanham-New, University of Surrey, UK (5). 90 
It assesses habitual sunlight exposure by season and during holidays. Questionnaire 91 
assessment of sunlight exposure has been shown to correlate with vitamin D status (24).  92 
Dietary vitamin D intake was assessed with DIETQ (Tinuviel Software, UK). This is a semi-93 
quantitative habitual food frequency intake questionnaire with computerised analysis based 94 
on the UK nutrient database (25). 95 
25OHD was measured in the Manchester Institute of Human Development, UK by liquid 96 
chromatography tandem mass spectrometry (LC-MS/MS). This laboratory participates in 97 
DEQAS and the assay is calibrated against the NIST standard.  25OHD2 was undetectable in 98 
most subjects. 99 
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Free (unbound) 25OHD was determined by immunoassay (26) (Future Diagnostics, 100 
Netherlands, inter-assay CV at 13.2pg/ml 5.3%). Free 25OHD can also be estimated by 101 
calculation from total 25OHD, DBP, albumin and their binding affinities, but this approach 102 
has limitations due to genetic variation in DBP, and the direct measurement by immunoassay 103 
is more closely correlated with serum PTH and calcium (27). 104 
1,25(OH)2D was measured by manual immunoassay after immunoextraction 105 
(ImmunoDiagnostic Systems, UK, inter-assay CV 6.0%, intra-assay CV 2.6%).  106 
DBP was measured by Quantikine manual immunoassay (R&D Systems, UK, inter-assay CV 107 
3.3%, intra-assay CV 3.9%). 108 
C-terminal telopeptide of type I collagen (CTX, bone resorption marker), procollagen type I 109 
N propeptide (PINP) and osteocalcin (bone formation markers) were measured by automated 110 
immunoassay (Cobas e411, Roche Diagnostics, Germany). Inter-assay CVs were: CTX 4.0%, 111 
PINP 4.1%, osteocalcin 2.2%. Bone alkaline phosphatase (bone ALP, bone formation 112 
marker) was measured by automated immunoassay (iSYS, ImmunoDiagnostic Systems, 113 
inter-assay CV 4.5%). 114 
Albumin, creatinine, calcium and PTH were measured by autoanalyser (Cobas c701, Roche 115 
Diagnostics, inter-assay precision <2.0% all tests). 116 
DBP genotyping was done by Sheffield Children’s Hospital, UK. The pyrosequencing assay 117 
was developed using PSQ software version 1.0.6 (Qiagen) to detect rs4588 and rs7041 118 
polymorphisms. 119 
25OHD half-life was measured with a 24 mcg orally administered tracer stable isotope of 120 
25OHD3 (3-
2
H-25-hydroxyvitamin D3 (6, 19, 19-d3)). The tracer was given dissolved in olive 121 
oil with a standard breakfast. Venous blood was taken at 6±1, 9±2, 27±2 and 30±2 days after 122 
9 
 
 
 
administration. 25OHD3 half-life was calculated from the terminal slope of the disappearance 123 
of d3-25OHD3, as t1⁄2=ln(2)/kB, where kB is the natural logarithm of the slope of the line of 124 
best fit from day 5 to day 30 (28). Tracer preparation and LC-MS/MS measurements (29) 125 
were performed at MRC Human Nutrition Research, Cambridge, UK. 126 
Bone mineral density and fat mass were assessed by dual energy X-ray absorptiometry 127 
(DXA) and high resolution peripheral quantitative tomography (HR-pQCT).  128 
Whole body, lumbar spine and hip DXA were performed with a Discovery densitometer 129 
(Hologic Inc, Waltham MA, USA). The short-term precision for the spine and hip are 1.0% 130 
and 1.1%. 131 
HR-pQCT images of the distal radius and tibia (4% site, non-dominant, non-fractured) were 132 
obtained using XtremeCT (Scanco Medical AG, Switzerland). Images were analysed with 133 
Scanco software (version 6). The short term precision of the BMD measurements is 0.2 to 134 
5.5%  (30).  135 
Statistics 136 
Normality was assessed using histograms.  Skewed variables were log10 transformed for 137 
analysis.  138 
Variables that differed between the three BMI groups were identified with analysis of 139 
variance (ANOVA). Effects of age group and gender were tested with analysis of covariance 140 
(ANCOVA).  Post-hoc testing for differences between pairs of BMI groups was adjusted for 141 
multiple comparisons using the Tukey method.  142 
Relationships between variables and BMI (as a continuous variable) were examined with 143 
univariate linear models.  Multiple linear regression models were used to adjust for age (as a 144 
continuous variable) and gender.   145 
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Correlations between variables were calculated with Spearman’s Rank test, and 95% 146 
confidence intervals were calculated by bootstrapping. 147 
Statistical analyses were performed with SPSS Version 21 and R Version 3.2.1. 148 
The fall/spring study (n=223) had 90% power at 5% two-sided significance to detect a 0.22 149 
correlation coefficient between BMI and 25OHD. For ANOVA, 65 participants per BMI 150 
group had 90% power to detect a standardised effect size of 0.26 at 5% two-sided 151 
significance.  152 
The winter study (n=106) had 90% power at 5% two-sided significance to detect a 0.30 153 
correlation coefficient between BMI and 25OHD. For ANOVA, 32 participants per BMI 154 
group had 90% power to detect a standardised effect size of 0.37 at 5% two-sided 155 
significance.  156 
For missing data report see Supplemental Table 2. 157 
 158 
Results 159 
Characteristics of study participants are given in Table 1. Dietary calcium intake did not 160 
differ between BMI groups (mg/day mean and 95% CI: normal weight 1072 (1002 to 1145), 161 
overweight 1074 (998 to 1158), obese 1055 (1001 to 1112)). The subset also assessed in 162 
winter were representative of the whole group (n=106: normal BMI = 34, overweight = 32, 163 
obese = 40; younger = 46, older = 60; male = 50, female = 56). 164 
Total 25OHD3 was lower in obese and overweight people than normal weight people in 165 
fall/spring, but not in winter (Figure 1). In fall/spring, 56% of overweight and obese people 166 
had 25OHD3 below 50nmol/l, compared with 37% of normal weight. In winter, 75% of 167 
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overweight and obese people had 25OHD3 below 50nmol/l, compared with 62% of normal 168 
weight. 169 
Total 25OHD3 in fall/spring was inversely correlated with BMI (adjusted for date of visit, age 170 
and gender; model adjusted R² = 0.339, p<0.001). For every five unit increase in BMI, total 171 
25OHD3 decreased by 10.0% (95% CI: 5.7 to 14.0%, p<0.001). After the same adjustments, 172 
total 25OHD3 was also negatively correlated with whole body fat mass (model adjusted R² 173 
=0.334, p<0.001). For every 10kg increase in fat mass, total 25OHD3 decreased by 11% 174 
(95% CI: 6 to 15%, p<0.001).  175 
Although total 25OHD3 did not differ by BMI group in winter, 25OHD3 was negatively 176 
correlated with BMI (adjusted for age and gender; model adjusted R
2 
0.172, p<0.001). For 177 
every five unit increase in BMI, 25OHD3 decreased by 8.2% (95% CI: 0.5 to 15.3%, 178 
p=0.038). 179 
Dietary vitamin D and sunlight exposure did not differ by BMI group (Table 2). The average 180 
hours of sunlight (irradiance measurement above 120 w/m2) in Sheffield during the period of 181 
the study measurements were 4.6 in fall/spring and 1.9 in winter (Data kindly provided by 182 
Weston Park Weather Station, Sheffield).  183 
DBP and albumin did not differ by BMI group, and adjustment for age and gender did not 184 
change this result (Table 2).  DBP genotype distribution (Gc1-1 47%, Gc2-1 42%, Gc2-2 185 
11%) was similar to other reported white European populations (16). Genotype distribution 186 
did not differ by BMI group and BMI did not differ by genotype. Total 25OHD3 187 
concentration did differ by genotype (mean nmol/l and 95% CI: Gc1-1 52.2 (47.2 to 57.6), 188 
Gc2-1 45.3 (40.9 to 50.3), Gc2-2 39.4 (32.1 to 48.3) p=0.024).  189 
25OHD3 half-life did not differ by BMI group (Table 2).  190 
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Free 25OHD was lower in the obese and overweight groups than normal weight in 191 
fall/spring. BMI was negatively correlated with free 25OHD (adjusted for date of visit, age 192 
and gender; model adjusted R² = 0.296, p<0.001).  For every five unit increase in BMI, free 193 
25OHD decreased by 12.3% (95% CI: 7.7 to 16.6%, p<0.001).  When total 25OHD was 194 
added to the model the relationship between free 25OHD and BMI was no longer significant 195 
(R
2 
= 0.619, p=0.16).   196 
Total 1,25(OH)2D was also lower in the obese and overweight groups than normal weight in 197 
fall/spring (Table 3).  198 
PTH did not differ by BMI group (Table 3) and was not correlated with BMI. Adjusting for 199 
age and gender did not change this result. CTX and osteocalcin were lower in the obese 200 
group than normal weight and overweight. Bone ALP and PINP did not differ between BMI 201 
groups (Table 3). 202 
BMD by DXA at the whole body, lumbar spine and hip, and by HR-pQCT at the distal radius 203 
and tibia was higher in the overweight and obese groups than normal weight (Table 3). 204 
Grip strength did not differ by BMI group. Adjustment for age and gender did not change this 205 
result. SPPB score was lower in the overweight and obese groups than normal weight. 206 
However, SPPB score was not correlated with 25OHD (Spearman’s rho -0.122, 95% CI: -207 
0.261 to 0.014, p=0.073). 208 
 209 
Discussion 210 
This is the first study to use the free 25OHD assay and stable isotope half-life method to 211 
investigate the effect of body weight on vitamin D metabolism. 212 
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As expected, total serum 25OHD is was lower at higher body weight (lower in obese than 213 
normal weight people in fall/spring, and negatively correlated with BMI in fall/spring and in 214 
winter).  We also identified that the biologically available free serum 25OHD and active 215 
hormone 1,25(OH)2D were lower in obesity. However, PTH was similar across BMI groups, 216 
(other studies have described higher PTH in obesity (15, 20, 31)), bone turnover was not 217 
higher (bone resorption was lower than normal weight and formation was similar), and BMD 218 
by DXA and HR-pQCT was higher at all measured sites. We have previously shown that 219 
bone microarchitecture is more favourable for bone strength in obese people, with greater 220 
cortical thickness and trabecular number (31). 221 
We investigated several possible mechanisms for the effects of body weight on vitamin D 222 
status. Dietary vitamin D intake and sunlight exposure were similar across BMI groups. A 223 
previous UK study also found that sunlight exposure did not vary with BMI (32). 224 
Lower total 25OHD in obesity was not due to differences in protein binding; free 25OHD 225 
was also lower and serum albumin, DBP and DBP genotype did not differ by BMI group. 226 
25OHD3 half-life did not differ by BMI group, so lower 25OHD in obesity is not due to more 227 
rapid metabolic clearance. 228 
After cutaneous synthesis and absorption, vitamin D is distributed into fat, muscle and other 229 
tissues (33), and when volume of distribution is greater, less vitamin D may be available for 230 
25-hydroxylation. 25OHD is also distributed into fat and muscle, and into serum (34) and all 231 
of these compartments are increased in obesity. Consistent with this, other investigators have 232 
reported that the summer rise in circulating 25OHD is blunted in obesity (32, 35). When 233 
exposed to UV-B, normal weight and obese people have similar cutaneous synthesis of 234 
vitamin D (49), but the serum 25OHD rise is smaller in obese people (18), consistent with our 235 
observation that the 25OHD difference between normal weight and obese is greater in 236 
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fall/spring than in winter. This theory is supported by evidence that serum 25OHD response 237 
to oral vitamin D dosing is BMI-dependent (31, 36).  238 
Due to the greater volume of distribution, if whole body vitamin D and 25OHD were similar 239 
in obese and normal weight people, measured serum concentrations would be lower in obese 240 
people (and conversely, people with low BMI may have relatively high serum 25OHD but 241 
lower whole body stores). Therefore, BMI may need to be considered when using serum 242 
25OHD as a marker of vitamin D status. 243 
It is possible that the lower serum 25OHD in obesity does reflect true vitamin D deficiency, 244 
but that adverse skeletal effects are countered by positive skeletal effects of obesity, such as 245 
increased loading, oestrogen synthesis from adipocyte aromatase, or adipocyte hormones 246 
such as leptin. 247 
Physical function score was poorer in obese people, but not correlated with 25OHD. Vitamin 248 
D and calcium supplementation may improve physical functioning in older people, but there 249 
is less evidence for benefit in young adults (34-36). Other factors such as less physical 250 
activity and fat infiltration of muscle might contribute to poorer function. It is possible that 251 
vitamin D maintains muscle integrity in older adults by preventing intramuscular fat 252 
accumulation (37), which might be relevant to muscle function in obesity.  253 
There are some limitations to this study. Dietary and sunlight exposure habits differ by 254 
geography and culture, and it is very possible that lower dietary vitamin D and sunlight 255 
exposure contribute to low 25OHD in obese people elsewhere. We did not measure volume 256 
of distribution directly; this would require an intravenous isotope and there are none available 257 
for human use. We did not measure intestinal calcium absorption. We used the R+D DBP 258 
assay; other DBP assays may give different results because the influence of DBP genotype 259 
varies by assay (38), but all participants were Caucasian which will have minimised genotype 260 
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variation (the genotype distribution varies by ethnic group) and DBP genotype distribution 261 
did not differ between the BMI groups. We also excluded effects of protein binding by direct 262 
measurement of free 25OHD.  263 
We have not assessed effects of low 25OHD beyond the musculoskeletal system. Vitamin D 264 
deficiency has been associated with diseases such as cancer and metabolic syndrome, where 265 
obesity is also a risk factor. However, there is not yet evidence for a causative role of vitamin 266 
D deficiency (39). 267 
In conclusion, it is well recognised that total serum 25OHD is low in obesity, but we have 268 
shown that biologically available free serum 25OHD and the active hormone 1,25(OH)2D are 269 
also lower at higher body weight. The likely cause of lower 25OHD in obesity is greater 270 
volume of distribution. The lower 25OHD in obesity was not associated with higher PTH or 271 
bone turnover, lower bone density or poorer physical function. BMI affects the relationship 272 
between serum 25OHD and bone health and lower serum 25OHD at higher body weight may 273 
not indicate at-risk skeletal health.   274 
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Table 1: Participant characteristics by BMI group.  
 
Results given as mean (SD)  
BMI group 
Female/Male 
(number) 
Age 
(years) 
Height 
(m) 
BMI 
(kg/m
2
) 
Fat mass 
(kg) 
Normal 
(18.5 to 24.9 kg/m
2
) 
43/34 55.9 (16.0) 1.68 (0.09) 22.8 (1.4) 19.2 (3.5) 
Overweight 
(25.0 to 29.9 kg/m
2
) 
28/35 50.6 (15.2) 1.72 (0.09) 27.6 (1.3) 27.6 (5.7) 
Obese 
(>30.0 kg/m
2
) 
42/41 56.6 (15.4) 1.69 (0.10) 35.4 (4.3) 40.7 (9.2) 
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Table 2: Possible contributors to low vitamin D in obesity.  
 
 
Dietary vitamin D and sunlight scores given as geometric mean (95% CI). ANOVA all 
p>0.05.  
BMI group 
Normal 
n = 77 
Overweight  
n=63 
Obese 
n=83 
Dietary vitamin D intake 
(µg) 
3.61 
(3.01, 4.34) 
3.05 
(2.50, 3.72) 
2.72 
(2.24, 3.31) 
Annual sunlight exposure 
score 
90.48 
(82.44, 98.53) 
96.34 
(86.69, 105.98) 
92.33 
(84.54, 100.13) 
Summer sunlight exposure 
score 
48.45  
(43.96, 53.74) 
51.15  
(45.37, 56.94) 
47.55  
(42.65, 52.46) 
Vitamin D binding protein 
(µg/ml) 
136.0  
(124.9,147.0) 
124.9 
(112.3, 137.6) 
130.5 
(120.7, 140.4) 
Albumin  
(g/l) 
46.0 
(45.3, 46.8) 
45.7  
(45.0, 46.4) 
45.1 
(44.2, 45.9) 
25OHD3 half-life  
(days) 
17.8  
(16.6, 19.1) 
17.0  
(15.8, 18.2) 
18.2 
(17.0, 19.1) 
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Table 3: Possible consequences of low vitamin D in obesity 
 
Measurements taken in fall/spring. Results given as geometric mean (95% CI). ANCOVA 
adjusted for age, gender (and date of visit for biochemistry) 
1
p<0.01, 
2
p<0.001.  
Means not sharing a common superscript letter are significantly different at p<0.05 based on 
post-hoc testing adjusted for multiple comparisons using the Tukey method. 
 
  
BMI group 
Normal 
n=77 
Overweight  
n=63 
Obese 
n=83 
Free 25OHD
2
  
(pmol/l) 
10.6a 
(9.4, 12.0) 
7.5b 
(6.5, 8.6) 
7.8b 
(6.9, 8.8) 
Total 1,25(OH)2D
1 
(pmol/l) 
95.0a 
(87.1, 103.7) 
79.4b 
(72.3, 87.1) 
78.5b 
(72.3, 85.3) 
PTH  
(ng/l) 
41.4
a 
(38.4, 44.7) 
41.4
a 
(37.6, 45.5) 
43.5
a
 
(40.5, 46.7) 
CTX
1 
(ng/l) 
0.45
a 
(0.40, 0.50) 
0.47
a 
(0.43, 0.51) 
0.38
b 
(0.35, 0.42) 
Osteocalcin
1 
(ng/ml) 
23.0
a 
(21.3, 24.8) 
22.0
a 
(20.5, 23.6) 
19.1
b 
(18.0, 20.4) 
PINP  
(ng/ml) 
40.8
a 
(36.9, 45.2) 
41.4
a 
(38.3, 44.8) 
37.8
a
  
(34.8, 41.0) 
Bone ALP  
(ng/ml) 
12.8
a
  
(11.7, 13.9) 
12.9
a 
(11.8, 14.0) 
12.7
a 
(11.8, 13.7) 
Whole body DXA BMD
2 
(g/cm
2
) 
1.07
a 
(1.05, 1.09) 
1.14
b
 
(1.11, 1.16) 
1.16
b 
(1.13, 1.18) 
Lumbar spine DXA BMD
2
 
(g/cm
2
) 
0.95
a 
(0.91, 0.98) 
1.04
b 
(1.01, 1.08) 
1.09
c 
(1.06, 1.13) 
Total hip DXA BMD
2 
(g/cm
2
) 
0.88
a
  
(0.85, 0.91) 
1.00
b
 
(0.97, 1.03) 
1.06
c 
(1.03, 1.09) 
Distal radius HR-pQCT BMD
2 
(mgHA/cm
3
) 
272.0
a 
(258.6, 286.0) 
303.0
b 
(290.6, 315.9) 
315.0
c 
(303.9, 326.5) 
Distal tibia HR-pQCT BMD
2 
(mgHA/cm
3
) 
280.0
a
 
(269.5, 290.8) 
312.2
b 
(298.3, 326.7) 
327.6
b 
(316.8, 338.8) 
Grip strength  
(kg) 
22.1
a 
(20.3, 23.9) 
24.1
a 
(21.6, 26.6) 
23.1
a
 
(21.0, 25.1) 
Short physical performance 
battery score
2 
9.5
a
  
(9.1, 9.9) 
9.1
b
  
(8.7, 9.4) 
8.3
c 
(8.0, 8.7) 
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Figure legends 
Figure 1: Total 25OHD3 (LC-MS/MS) by BMI group in fall/spring (n =223) (A) and in 
winter (n=106) (B).  
Results shown as geometric mean and 95% confidence interval. ANCOVA adjusted for date 
of visit (April/May vs September/October), age group and gender. 
 
